Safety and Efficacy of Brimonidine in Patients With Glaucoma or Ocular Hypertension

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00168363

Enrollment

207

Registered

2005-09-15

Start date

2005-01-31

Completion date

2006-08-31

Last updated

2011-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma, Ocular Hypertension

Brief summary

This Study will evaluate the safety and efficacy of brimonidine in patients with glaucoma or ocular hypertension

Interventions

DRUGbrimonidine

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* ocular hypertension or glaucoma in both eyes * currently treated with brimonidine * requires IOP-lowering therapy in both eyes

Exclusion criteria

* uncontrolled systemic disease * known allergy or sensitivity to brimonidine

Design outcomes

Primary

Measure	Time frame
lowering of intraocular pressure	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 5, 2026